Atropos Health Expands Oncology Precision Medicine Capabilities with Publication of New AI Algorithms for Rare Disease and Integration of ASCO Guidelines

Audio By Carbonatix

PALO ALTO, Calif.--(BUSINESS WIRE)--Dec 5, 2025--

Atropos Health, a pioneer in translating real-world clinical data into personalized real-world evidence (RWE) and insights, today announced the publication of additional AI tools for patient monitoring for existing paroxysmal nocturnal hemoglobinuria (PNH)—a rare, serious blood disorder. The progression monitoring tools are in addition to the previously-published algorithm to improve earlier diagnosis that was announced prior.

Atropos Health has developed additional AI models for progression monitoring in already-diagnosed PNH patients, aimed at reducing the risk of developing serious sequelae of PNH including thrombosis, organ dysfunction, or anemia and worsening hemolytic anemia. The AI progression monitoring tools are now available for use by health systems.

Dr. Sandeep Jain, Director Medical Innovation Hematology & Oncology at Atropos Health will be presenting “Early identification of patients likely to benefit from paroxysmal nocturnal hemoglobinuria workup using machine learning on large-scale real-world data” at the ASH Annual Meeting and Exposition in Orlando, Florida. The poster session “803 Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster II” will be presented on December 7, 2025 from 6:00 PM - 8:00 PM in room OCCC - West Halls B3-B4.

In addition to the additional algorithms, Atropos Health is also announcing the integration of ASCO Guidelines for the Oncology offering. Atropos Health is integrating ASCO’s clinical practice guidelines into the platform to equip oncologists and researchers with the latest guidelines and information to guide personalized patient care. Physicians are now able to use the Atropos platform to easily access ASCO Guidelines, which provide evidence-based, treatment and care recommendations for patients.

“The future of evidence based medicine in oncology is being transformed by data and technology. With these two announcements - integration of gold-standard ASCO Guidelines alongside the publication of additional AI models—we are progressing the advancement of precision medicine,” said Dr. Brigham Hyde, CEO and co-founder at Atropos Health. "By democratizing access to these models via publishing them publicly and allowing users to access these oncology guidelines within our platform, we are empowering clinicians to navigate complex patient journeys with unprecedented clarity and deliver personalized, evidence-driven care.”

Today’s announcement comes on the heels of the recent Atropos Evidence™ Agent launch, an expert agent in generating real-world evidence RWE. Atropos Health is now embedding personalized evidence within the EHR at Stanford Health Care with data from ChatEHR to provide improved personalized RWE at the point of care. As part of a pilot with Microsoft, Atropos Health will combine ambient encounter data from Dragon Copilot with the Atropos Evidence™ Agent.

About Atropos Health

Atropos Health is the developer of GENEVA OS®, the operating system for rapid healthcare evidence across a robust network of real-world data. Healthcare and life science organizations work with Atropos Health to close evidence gaps from bench to bedside, improve individual patient outcomes with data-driven care, expedite research that advances the field of medicine, and more. We aim to transform healthcare with timely, relevant, real-world evidence.

To learn more about Atropos Health, visit www.atroposhealth.com, connect through LinkedIn, or follow on X @AtroposHealth.

View source version on businesswire.com:https://www.businesswire.com/news/home/20251205760493/en/

CONTACT: Hannah Melillo

[email protected]

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: ONCOLOGY HEALTH TECHNOLOGY HEALTH TECHNOLOGY SOFTWARE ARTIFICIAL INTELLIGENCE

SOURCE: Atropos Health

Copyright Business Wire 2025.

PUB: 12/05/2025 09:37 AM/DISC: 12/05/2025 09:38 AM

http://www.businesswire.com/news/home/20251205760493/en